Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study

Michael J. Allingham,Priyatham S. Mettu,Scott W. Cousins

Ophthalmology science（2022）

引用 9|浏览0

暂无评分

摘要

Elamipretide appeared to be generally safe and well tolerated in treating intermediate AMD and HRD. Exploratory analyses demonstrate a positive effect on visual function, particularly under low-luminance conditions. Further study of elamipretide for treatment of intermediate AMD with HRD is warranted.

查看译文

关键词

Dry age-related macular degeneration,Elamipretide,Mitochondrial dysfunction,Phase 1 clinical trial,Retina

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要